Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement

BACKGROUND: XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with metastatic colorectal cancer (MCRC). A US cost-minimization study found that the two regimens had similar costs from a healthcare provider pers...

Descripción completa

Detalles Bibliográficos
Autores principales: Tse, Vicki C, Ng, Wai Tong, Lee, Victor, Lee, Anne WM, Chua, Daniel TT, Chau, June, McGhee, Sarah M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146941/
https://www.ncbi.nlm.nih.gov/pubmed/21740590
http://dx.doi.org/10.1186/1471-2407-11-288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146941/
https://www.ncbi.nlm.nih.gov/pubmed/21740590
http://dx.doi.org/10.1186/1471-2407-11-288

Ejemplares similares